10-Point Compounding Pharmacy Verification Checklist

The same framework PeptidesBeat applies to every pharmacy we evaluate for the directory. Use it to verify any compounding pharmacy you are considering, in any state, before you rely on it. This is a verification framework — not medical advice, and not an endorsement of any pharmacy.

Why the checklist exists

Since the April 15, 2026 FDA reclassification, licensed 503A compounding pharmacies may legally prepare the twelve reclassified peptides under valid patient-specific prescriptions. But legality varies by state, and quality varies by pharmacy. The gap between a pharmacy that merely exists and one that compounds reliably is exactly what these ten points measure. None of them are optional in our process.

The 10 points

1. State pharmacy license

Confirm the pharmacy holds a current, active license from the state board of pharmacy in the state where it operates. Every state board publishes a free online license lookup. If the license is expired, suspended, or shows repeated disciplinary action, stop there.

2. Non-resident registration for out-of-state pharmacies

If the pharmacy is based out of state, it must hold a non-resident pharmacy registration in the state where you receive the prescription. Verify both sides: the home-state license and the non-resident registration. Many states list non-resident registrations in the same public lookup.

3. 503A vs. 503B designation

Confirm whether the pharmacy compounds under a 503A (patient-specific prescription) or 503B (office-use / bulk) license. The twelve reclassified peptides sit on the 503A bulks framework. A pharmacy that cannot state its designation clearly, or that conflates the two, has not demonstrated the basic regulatory literacy the category now requires.

4. PCAB accreditation

PCAB (Pharmacy Compounding Accreditation Board, administered by URAC) accreditation is voluntary and is the strongest third-party marker of compounding quality. It requires the pharmacy to submit to outside inspection of facilities, processes, and testing. Lack of accreditation is not automatically disqualifying \u2014 but it should raise the burden on every other point.

5. Bulk substance sourcing

The pharmacy must source the peptide's bulk substance from a supplier that is registered and compliant with FDA bulk drug substance requirements. Ask directly where the substance is sourced, and whether the supplier appears on FDA's registered bulk substance list. A pharmacy that cannot account for its raw material chain is a pharmacy to avoid.

6. Prescription requirement

A compliant 503A pharmacy will not compound a reclassified peptide without a valid, patient-specific prescription from a licensed prescriber. Any pharmacy that offers the twelve peptides "no prescription needed," "for research only," or in wellness bundles without a prescription is operating outside the post-April-15 framework \u2014 and should be reported to the state board.

7. Testing and quality control

Ask what finished-product testing the pharmacy performs: potency, endotoxin, sterility, and identity. Testing is required under compounding standards (USP 795/797/800 context) and is the difference between a pharmacy that verifies what it ships and one that only fills vials. Written answers matter more than assurances.

8. Labeling and beyond-use dating

Every compounded product must carry a label with the patient's name, the drug and strength, the pharmacy, the prescriber, the date compounded, and a beyond-use date. If a pharmacy is vague about beyond-use dating or ships unlabeled product, that is a hard fail.

9. Enforcement and recall history

Search the pharmacy's name against FDA warning letters, state board actions, and recall databases before relying on it. FDA posts warning letters publicly; state boards post disciplinary actions. A single old citation is not automatically disqualifying \u2014 a pattern, or a recent one involving sterility or potency, is.

10. Pharmacist availability and documentation

A compounding pharmacist should be reachable to answer questions about the specific product, its beyond-use date, and its documentation. The pharmacy should maintain batch records it can produce on request. If the pharmacist is unreachable or the records are "not available," treat that as a red flag regardless of everything else.

What this checklist is not

This checklist verifies regulatory standing and operational quality. It does not evaluate whether any peptide is appropriate for you, what dose to use, or whether you need a prescription \u2014 those are questions for a licensed healthcare provider. It also does not rank or endorse any specific pharmacy. For the legal landscape behind the checklist, see the FDA peptide timeline and the July PCAC meeting breakdown.

Frequently asked questions

Is the 10-point checklist a recommendation to buy from any specific pharmacy?
No. The checklist is a verification framework, not an endorsement. It exists to help you confirm that a pharmacy you are already considering is licensed, registered, accredited where applicable, and compounding within the post-April-15 regulatory framework.

Where can I verify a pharmacy's license and registration?
Start with the state board of pharmacy in the state where the pharmacy operates and, for out-of-state fulfillment, the state where you live. Most state boards publish free online license lookup tools. The National Association of Boards of Pharmacy (NABP) also maintains verification resources.

Does PCAB accreditation matter for every compounding pharmacy?
PCAB accreditation is voluntary but is widely treated as the strongest third-party marker of compounding quality. A pharmacy can be fully legal without it, but accreditation signals that the pharmacy has submitted to outside inspection of its compounding processes.

What changed for compounding pharmacies on April 15, 2026?
The FDA removed twelve therapeutic peptides \u2014 including BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF \u2014 from Category 2 of the 503A bulk drug substances evaluation framework, moving them to an interim evaluation tier pending final Bulks List placement.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.